148 related articles for article (PubMed ID: 37305548)
1. The efficacy and safety of Trilaciclib in preventing chemotherapy-induced myelosuppression: a systematic review and meta-analysis of randomized controlled trials.
Qiu J; Sheng D; Lin F; Jiang P; Shi N
Front Pharmacol; 2023; 14():1157251. PubMed ID: 37305548
[No Abstract] [Full Text] [Related]
2. Trilaciclib prior to chemotherapy reduces the usage of supportive care interventions for chemotherapy-induced myelosuppression in patients with small cell lung cancer: Pooled analysis of three randomized phase 2 trials.
Ferrarotto R; Anderson I; Medgyasszay B; García-Campelo MR; Edenfield W; Feinstein TM; Johnson JM; Kalmadi S; Lammers PE; Sanchez-Hernandez A; Pritchett Y; Morris SR; Malik RK; Csőszi T
Cancer Med; 2021 Sep; 10(17):5748-5756. PubMed ID: 34405547
[TBL] [Abstract][Full Text] [Related]
3. Myelopreservation with Trilaciclib in Patients Receiving Topotecan for Small Cell Lung Cancer: Results from a Randomized, Double-Blind, Placebo-Controlled Phase II Study.
Hart LL; Ferrarotto R; Andric ZG; Beck JT; Subramanian J; Radosavljevic DZ; Zaric B; Hanna WT; Aljumaily R; Owonikoko TK; Verhoeven D; Xiao J; Morris SR; Antal JM; Hussein MA
Adv Ther; 2021 Jan; 38(1):350-365. PubMed ID: 33123968
[TBL] [Abstract][Full Text] [Related]
4. Myeloprotective Effects of Trilaciclib Among Patients with Small Cell Lung Cancer at Increased Risk of Chemotherapy-Induced Myelosuppression: Pooled Results from Three Phase 2, Randomized, Double-Blind, Placebo-Controlled Studies.
Hussein M; Maglakelidze M; Richards DA; Sabatini M; Gersten TA; Lerro K; Sinielnikov I; Spira A; Pritchett Y; Antal JM; Malik R; Beck JT
Cancer Manag Res; 2021; 13():6207-6218. PubMed ID: 34408488
[TBL] [Abstract][Full Text] [Related]
5. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
6. Exploratory composite endpoint demonstrates benefit of trilaciclib across multiple clinically meaningful components of myeloprotection in patients with small cell lung cancer.
Dómine Gómez M; Csőszi T; Jaal J; Kudaba I; Nikolov K; Radosavljevic D; Xiao J; Horton JK; Malik RK; Subramanian J
Int J Cancer; 2021 Oct; 149(7):1463-1472. PubMed ID: 34109630
[TBL] [Abstract][Full Text] [Related]
7. Effects of Trilaciclib on Chemotherapy-Induced Myelosuppression and Patient-Reported Outcomes in Patients with Extensive-Stage Small Cell Lung Cancer: Pooled Results from Three Phase II Randomized, Double-Blind, Placebo-Controlled Studies.
Weiss J; Goldschmidt J; Andric Z; Dragnev KH; Gwaltney C; Skaltsa K; Pritchett Y; Antal JM; Morris SR; Daniel D
Clin Lung Cancer; 2021 Sep; 22(5):449-460. PubMed ID: 33895103
[TBL] [Abstract][Full Text] [Related]
8. Budget impact analysis of trilaciclib for decreasing the incidence of chemotherapy-induced myelosuppression in patients with extensive-stage small cell lung cancer in the United States.
Abraham I; Goyal A; Deniz B; Moran D; Chioda M; MacDonald KM; Huang H
J Manag Care Spec Pharm; 2022 Apr; 28(4):435-448. PubMed ID: 35100006
[No Abstract] [Full Text] [Related]
9. Primary prophylactic colony-stimulating factors for the prevention of chemotherapy-induced febrile neutropenia in breast cancer patients.
Renner P; Milazzo S; Liu JP; Zwahlen M; Birkmann J; Horneber M
Cochrane Database Syst Rev; 2012 Oct; 10():CD007913. PubMed ID: 23076939
[TBL] [Abstract][Full Text] [Related]
10. Myeloprotection with trilaciclib in Chinese patients with extensive-stage small cell lung cancer receiving chemotherapy: Results from a randomized, double-blind, placebo-controlled phase III study (TRACES).
Cheng Y; Wu L; Huang D; Wang Q; Fan Y; Zhang X; Fan H; Yao W; Liu B; Yu G; Pan Y; Xu F; He Z; Dong X; Ma R; Min X; Ge X; Chen H; Liu Q; Hu Y; Liu Y; Yang C; Yang Y; Li X; Zhou L
Lung Cancer; 2024 Feb; 188():107455. PubMed ID: 38224653
[TBL] [Abstract][Full Text] [Related]
11. New Advances in Supportive Care: Chemoprotective Agents as Novel Opportunities in Geriatric Oncology.
Balducci L; Falandry C; List A
Curr Oncol Rep; 2022 Dec; 24(12):1695-1703. PubMed ID: 35986858
[TBL] [Abstract][Full Text] [Related]
12. Trilaciclib plus chemotherapy versus chemotherapy alone in patients with metastatic triple-negative breast cancer: a multicentre, randomised, open-label, phase 2 trial.
Tan AR; Wright GS; Thummala AR; Danso MA; Popovic L; Pluard TJ; Han HS; Vojnović Ž; Vasev N; Ma L; Richards DA; Wilks ST; Milenković D; Yang Z; Antal JM; Morris SR; O'Shaughnessy J
Lancet Oncol; 2019 Nov; 20(11):1587-1601. PubMed ID: 31575503
[TBL] [Abstract][Full Text] [Related]
13. Trilaciclib prior to chemotherapy and atezolizumab in patients with newly diagnosed extensive-stage small cell lung cancer: A multicentre, randomised, double-blind, placebo-controlled Phase II trial.
Daniel D; Kuchava V; Bondarenko I; Ivashchuk O; Reddy S; Jaal J; Kudaba I; Hart L; Matitashvili A; Pritchett Y; Morris SR; Sorrentino JA; Antal JM; Goldschmidt J
Int J Cancer; 2021 May; 148(10):2557-2570. PubMed ID: 33348420
[TBL] [Abstract][Full Text] [Related]
14. Trilaciclib and the economic value of multilineage myeloprotection from chemotherapy-induced myelosuppression among patients with extensive-stage small cell lung cancer treated with first-line chemotherapy.
Abraham I; Onyekwere U; Deniz B; Moran D; Chioda M; MacDonald K; Huang H
J Med Econ; 2021 Nov; 24(sup1):71-83. PubMed ID: 34873975
[TBL] [Abstract][Full Text] [Related]
15. The impact of myelosuppression on quality of life of patients treated with chemotherapy.
Crawford J; Herndon D; Gmitter K; Weiss J
Future Oncol; 2024 Apr; ():. PubMed ID: 38587388
[TBL] [Abstract][Full Text] [Related]
16. Real-World Outcomes of Trilaciclib Among Patients with Extensive-Stage Small Cell Lung Cancer Receiving Chemotherapy.
Goldschmidt J; Hart L; Scott J; Boykin K; Bailey R; Heritage T; Lopez-Gonzalez L; Zhou ZY; Edwards ML; Monnette A; Ogbonnaya A; Deyoung K; Venkatasetty D; Shi P; Aton L; Huang H; Conkling PR; Gordan L
Adv Ther; 2023 Oct; 40(10):4189-4215. PubMed ID: 37490258
[TBL] [Abstract][Full Text] [Related]
17. Assessing the Optimal Regimen: A Systematic Review and Network Meta-Analysis of the Efficacy and Safety of Long-Acting Granulocyte Colony-Stimulating Factors in Patients with Breast Cancer.
You Z; Zhang H; Huang Y; Zhao L; Tu H; Zhang Y; Lin X; Liang W
Cancers (Basel); 2023 Jul; 15(14):. PubMed ID: 37509336
[TBL] [Abstract][Full Text] [Related]
18. Single or combined immune checkpoint inhibitors compared to first-line platinum-based chemotherapy with or without bevacizumab for people with advanced non-small cell lung cancer.
Ferrara R; Imbimbo M; Malouf R; Paget-Bailly S; Calais F; Marchal C; Westeel V
Cochrane Database Syst Rev; 2020 Dec; 12(12):CD013257. PubMed ID: 33316104
[TBL] [Abstract][Full Text] [Related]
19. CDK4/6 inhibition enhances antitumor efficacy of chemotherapy and immune checkpoint inhibitor combinations in preclinical models and enhances T-cell activation in patients with SCLC receiving chemotherapy.
Lai AY; Sorrentino JA; Dragnev KH; Weiss JM; Owonikoko TK; Rytlewski JA; Hood J; Yang Z; Malik RK; Strum JC; Roberts PJ
J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33004541
[TBL] [Abstract][Full Text] [Related]
20. Prophylactic antibiotics or G(M)-CSF for the prevention of infections and improvement of survival in cancer patients receiving myelotoxic chemotherapy.
Skoetz N; Bohlius J; Engert A; Monsef I; Blank O; Vehreschild JJ
Cochrane Database Syst Rev; 2015 Dec; 2015(12):CD007107. PubMed ID: 26687844
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
